There’s no “silver bullet” for this problem, which is largely driven by clinical inertia, but some efforts are chipping away ...

NYHA class was more likely to have improved at 1 year in the treatment ... EF = ejection fraction; HF = heart failure; HR = hazard ratio; I-PRESERVE = irbesartan in heart failure with preserved ...

Therapies are needed for patients with heart failure with mildly reduced or preserved ejection fraction. New research findings on the nonsteroidal mineralocorticoid receptor antagonist finerenone ...

Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDI ...

But there are tools that exist that can improve outcomes, such as guideline-directed medical therapy (GDMT ... suffering from ...

Duke-NUS scientists and their collaborators have discovered a potential new treatment for heart failure with preserved ...

The study showed that treatment with Farxiga ... cardiovascular death or worsening heart failure in patients with both mildly reduced and preserved ejection fraction, said AZ.

Risk for heart failure events is decreased and health status is improved in patients with HFmrEF and HFpEF receiving finerenone.

EF = ejection fraction; HF = heart failure; HR = hazard ratio; I-PRESERVE = irbesartan in heart failure with preserved systolic function; LV = left ventricular; MI = myocardial infarction ...